Getting Organized on Abuse-Deterrent Opioids: FDA Calls For Volunteers Ahead of Oct. 30-31 Meeting
This article was originally published in RPM Report
Executive Summary
FDA is planning a two-day workshop on issues related to abuse-deterrent opioid formulations, and wants to hear unified presentations from the brand and generic industry. That is easier said than done.
You may also be interested in...
Pfizer Gets Abuse-Deterrent Claim on One Pain Drug, Then Drops Development of Another
Pfizer got its first abuse-deterrent claim for its pain therapy Embeda. But it has also ended an agreement to develop another potential abuse-deterrent pain drug.
Seeking Guidance On Abuse-Deterrence: Sponsors Fall Short, Congress Urges Action
Congressional appropriators are urging FDA to move quickly to finalize guidance on abuse deterrence claims for opioids—and to take the next step and prohibit marketing of products that don’t deter abuse. FDA says the science isn’t there yet, and two sponsors join the list of those who have failed to clear the hurdle.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.